Akebia Therapeutics (AKBA) Accounts Payables (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Accounts Payables of $8.4 million for Q1 2026, down 33.75% year-over-year from $12.7 million in Q1 2025, and down 60.42% quarter-over-quarter from $21.2 million in Q4 2025.
Akebia Therapeutics (AKBA) Accounts Payables (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Accounts Payables for 14 consecutive years, with $8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 33.75% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (down 33.75% YoY), while the FY2025 annual figure was $21.2 million, up 39.56% from the prior year.
- Accounts Payables eased to $8.4 million in Q1 2026 per AKBA's latest filing, from $21.2 million in the prior quarter.
- Across five years, Accounts Payables topped out at $24.9 million in Q2 2022 and bottomed at $8.4 million in Q1 2026.
- Historically, Accounts Payables has averaged $14.4 million across 5 years, with a median of $12.7 million in 2025.
- Annual changes were most pronounced in 2023 — Accounts Payables tumbled 54.14% — and 2024, when it surged 49.3%.
- Akebia Therapeutics' Accounts Payables stood at $18.0 million in 2022, then fell by 18.79% to $14.6 million in 2023, then climbed by 3.72% to $15.2 million in 2024, then soared by 39.56% to $21.2 million in 2025, then plunged by 60.42% to $8.4 million in 2026.
- Business Quant data shows AKBA's Accounts Payables at $8.4 million in Q1 2026, $21.2 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 356.00 Mn |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 9.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.42 Mn |
| Mar 31, 2026 | 8.39 Mn |
| Dec 31, 2025 | 21.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 11.55 Mn |
| Mar 31, 2025 | 12.66 Mn |
| Dec 31, 2024 | 15.18 Mn |
| Sep 30, 2024 | 13.49 Mn |
| Jun 30, 2024 | 10.11 Mn |
| Mar 31, 2024 | 11.88 Mn |
| Dec 31, 2023 | 14.64 Mn |
| Sep 30, 2023 | 9.04 Mn |
| Jun 30, 2023 | 11.78 Mn |
| Mar 31, 2023 | 12.58 Mn |
| Dec 31, 2022 | 18.02 Mn |
| Sep 30, 2022 | 19.71 Mn |
| Jun 30, 2022 | 24.94 Mn |
| Mar 31, 2022 | 19.47 Mn |
| Dec 31, 2021 | 33.59 Mn |
| Sep 30, 2021 | 28.81 Mn |